Articles related to EVIDENCE REVIEW

A systematic review of 43 randomized controlled trials found high-certainty evidence that multiple CGRP-targeted therapies reduced monthly migraine headache days by approximately 2 days versus placebo in adults with chronic migraine.

In a 794-patient randomized trial, early-stage type 2 diabetes patients uncontrolled on metformin who received tirzepatide achieved nearly twice the HbA1c reduction of those on intensified conventional care at 2 years, and 60% reached normoglycemia (HbA1c <5.7%), compared to 24% in the ICC arm.

A narrative review of UCLA spice research found associations between common culinary spices — cinnamon, turmeric, red pepper, and spice blends — and glucose regulation, gut microbiome composition, and cognitive markers, though most findings stem from small trials and in vitro work using supratherapeutic doses.

Bausch + Lomb launched PreserVision AREDS3, a reformulation of its established AREDS2 supplement adding a proprietary B-vitamin complex, citing a narrative review of more than 20 human studies linking B-vitamin supplementation to reduced AMD risk.

A JAMA Psychiatry network meta-analysis ranked lumateperone highest for efficacy and aripiprazole highest for acceptability among five FDA-approved adjunctive atypical antipsychotics for major depressive disorder.

A systematic review of 27 studies found behavioral sleep interventions — particularly CBT-I and sleep hygiene — reduced BMI and body weight in adults with poor sleep health, with the largest effects among patients with obesity.